Compare WEAV & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEAV | LAB |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.7M | 488.4M |
| IPO Year | 2021 | 2008 |
| Metric | WEAV | LAB |
|---|---|---|
| Price | $4.88 | $0.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $11.00 | $1.35 |
| AVG Volume (30 Days) | 1.9M | ★ 2.4M |
| Earning Date | 05-20-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.50 | ★ 44.68 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $239,024,000.00 | $101,937,000.00 |
| Revenue This Year | $17.20 | N/A |
| Revenue Next Year | $13.74 | $2.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.99 | N/A |
| 52 Week Low | $4.72 | $0.92 |
| 52 Week High | $12.19 | $1.72 |
| Indicator | WEAV | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 33.99 | 23.76 |
| Support Level | N/A | N/A |
| Resistance Level | $7.31 | $1.41 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 15.71 | 3.02 |
Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.